In 2015, a randomized, prospective, double blinded, placebo controlled, phase II clinical trial to determine the activity of PDE5 inhibitors on immune function in head and neck squamous cell carcinoma (HNSCC) patients was conducted [279]. The gene discussed is PDE5A; the disease is head and neck squamous cell carcinoma.